Epizyme Inc., which develops cancer therapies, has leased 18,396 square feet at 325 Vassar St. in Cambridge.

The Vassar Street property will serve as Epizyme’s corporate headquarters and will more than double the size of the life sciences company’s previous location. Epizyme will occupy space on the second floor and is expected to relocate in April, according to a statement.

"Our new location supports the growth catalyzed by our scientific advances and our recently announced partnership with GlaxoSmithKline and is an important step in the execution of our strategy to build a new, leading biopharmaceutical company," said Jason Rhodes, EVP and CBO of Epizyme. "We anticipate that 325 Vassar, and the flexibility offered by its Universal Flex Lab, will meet our needs for the foreseeable future."

Epizyme is the first tenant signed by BioMed Realty Trust at 325 Vassar St. since its redevelopment as a Universal Flex Lab building. The Universal Flex Lab concept was designed to meet the needs of companies that require a high level of flexibility, such as those anticipating growth or those with dynamic requirements. Laboratory space, offices and meeting rooms can be installed and reconfigured quickly to maximize productivity and space utilization. Universal Flex Lab space reduces tenant costs because users can customize their space without excessive construction expenses.

"Today’s life science companies appreciate having the ability to reconfigure their labs quickly as their technology platform evolves," said Steven Purpura, partner, Richards Barry Joyce & Partners (RBJ&P). "BioMed’s Universal Flex Lab space truly provides maximum flexibility and as such has been very well received by prospective tenants."

Jon Varholak and Eric Smith, of RBJ&P, represented Epizyme in the transaction. Purpura represented BioMed Realty Trust.